drug · antibody

UNLOXCYT

updated 2mo ago

by $CCCC C4 Therapeutics, Inc.🔗 ChEMBL

community read0 votes

Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for head and neck squamous cell carcinoma and 2 investigational indications.

targets

Programmed cell death 1 ligand 1

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

UNLOXCYT

trade names

Unloxcyt

generic

COSIBELIMAB-IPDL

MOA

12.1. Mechanism of Action PD-L1 may be expressed on tumor cells and tumor-infiltrating immune cells and can contribute to the inhibition of the anti-tumor immune response in the tumor microenvironment. Binding of PD-L1 to the PD-1 and B7.1 receptors found on T cells and antigen presenting cells suppresses cytotoxic T-cell activity, T-cell proliferation, and cytokine production. Cosibelimab-ipdl binds PD-L1 and blocks the interaction between PD-L1 and its receptors PD-1 and B7.1. This interaction releases the inhibitory effects of PD-L1 on the anti-tumor immune response. Cosibelimab-ipdl has also been shown to induce antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro.

indication

1. INDICATIONS AND USAGE UNLOXCYT is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. UNLOXCYT is a programmed death ligand-1 (PD-L1) blocking antibody indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.

UNLOXCYT

targets

all catalysts(0)

News(0)

Report a data issue

comments(0)

🐶 often sniffed alongside